Cite
Differential antitumor activity of aflibercept and bevacizumab in patient-derived xenograft models of colorectal cancer
MLA
Donald A. Bergstrom, et al. “Differential Antitumor Activity of Aflibercept and Bevacizumab in Patient-Derived Xenograft Models of Colorectal Cancer.” Molecular Cancer Therapeutics, vol. 13, no. 6, Apr. 2014. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....532f3cd14bac8f45dc9df50e1969809b&authtype=sso&custid=ns315887.
APA
Donald A. Bergstrom, Catherine Geslin, Jack Pollard, Marielle Chiron, Loic Vincent, Nina Baltes, Rebecca G. Bagley, Parminder Mankoo, & Christophe Henry. (2014). Differential antitumor activity of aflibercept and bevacizumab in patient-derived xenograft models of colorectal cancer. Molecular Cancer Therapeutics, 13(6).
Chicago
Donald A. Bergstrom, Catherine Geslin, Jack Pollard, Marielle Chiron, Loic Vincent, Nina Baltes, Rebecca G. Bagley, Parminder Mankoo, and Christophe Henry. 2014. “Differential Antitumor Activity of Aflibercept and Bevacizumab in Patient-Derived Xenograft Models of Colorectal Cancer.” Molecular Cancer Therapeutics 13 (6). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....532f3cd14bac8f45dc9df50e1969809b&authtype=sso&custid=ns315887.